Dr. Martin Reck on Docetaxel/Ramucirumab in NSCLC | OncLive

Dr. Martin Reck on Docetaxel/Ramucirumab in NSCLC

July 14, 2016

Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discuses the REVEL trial, a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).

Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discuses the REVEL trial, a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).

A significant improvement in overall survival in favor of the combination of docetaxel with ramucirumab, says Reck. An improvement in progression-free survival (PFS) and response rate was also observed.

This important in efficacy was seen independent from histology. An additional analysis was performed on patients who were chemotherapy refractory patients. An additional benefit was seen in this poor prognostic group, said Reck.


x